| Document |
Document Title |
|
WO/2022/164150A1 |
Provided are a method for efficiently producing nafamostat mesylate using a simple process, and a method for producing 6-amidino-2-naphthol mesylate, which is an intermediate of nafamostat mesylate production, at high yield and under mil...
|
|
WO/2022/162604A1 |
The present invention relates to a novel cocrystal, a pharmaceutical composition comprising same and a preparation method therefor. By using the cocrystal of the present invention, cancers, inflammatory diseases, or viral infection disea...
|
|
WO/2022/148053A1 |
The present invention relates to the technical field of pharmaceutical preparations, and in particular to a purification method for metformin hydrochloride, a metformin hydrochloride sustained release tablet and a preparation method ther...
|
|
WO/2022/133586A1 |
Metformin prevents hyperglycaemia-associated, oxidative stress-induced vascular endothelial dysfunction at low concentrations (~1 µM). The orphan nuclear receptor Nr4al (i.e. Nur77) is involved in the protective activity, which can be r...
|
|
WO/2022/106505A1 |
The present invention relates to compounds comprising two biguanidyl radicals that can be useful as anti-inflammatory agent, and also to new compounds comprising two biguanidyl radicals and their use as a drug, in particular for treating...
|
|
WO/2022/097813A1 |
The present invention relates to an eco-friendly and highly efficient method for preparing an ester compound based on an esterification reaction using a salt ion-exchange method, and an ester compound thereof. In conventional esterificat...
|
|
WO/2022/091065A1 |
In a cocrystal, a pharmaceutical composition comprising same, and a preparation method therefor, of the present invention, a novel cocrystal comprises niclosamide and nafamostat, or a pharmaceutically acceptable salt thereof. The novel c...
|
|
WO/2022/082859A1 |
Provided is a refining method for an amino acid or derivatives thereof, comprising: (1) preparing a saturated aqueous solution of an amino acid or derivatives thereof from a crude product of the amino acid or derivatives thereof at prese...
|
|
WO/2022/067043A1 |
The present invention includes a co-crystal of creatine and citric acid obtained by milling, methods of making the same that include a process for the preparation of co-amorphous formulation of creatine and citric acid, the process compr...
|
|
WO/2022/048909A1 |
The present invention concerns a modified method for preparing guanidine acetic acid (GAA) by reacting cyanamide with an excess molar amount of glycine in an aqueous reaction mixture in the presence of a base that avoids high molar amoun...
|
|
WO/2022/048913A1 |
The present invention refers to a method for preparing guanidino acetic acid by reacting cyanamide and glycine in an aqueous reaction mixture in the presence of a base, wherein the ammonia content in the reaction mixture is controlled to...
|
|
WO/2022/045163A1 |
The present invention provides a guanidine fatty acid salt production method through which liquid surface elevation, caused by carbon dioxide generated during production of guanidine fatty acid salt, can be suppressed. This guanidine fat...
|
|
WO/2022/027122A1 |
The present invention is related to compositions containing only natural products for the treatment of erectile and sexual dysfunction (ESD). More specifically relates to compositions containing Cannabis extract, and other herbal extract...
|
|
WO/2022/022448A1 |
The present invention belongs to the pharmaceutical field. Specifically, the present invention relates to a neuraminidase inhibitor compound as represented by formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, or a ...
|
|
WO/2022/016288A1 |
Disclosed herein are cannabinoid salt compounds formed by mixing an acidic cannabinoid compound with a base. According to embodiments of the present disclosure, the base is selected at least for having a low toxicity. Also disclosed are ...
|
|
WO/2021/253087A1 |
The present invention relates to compounds of Formula I which form hydrogels upon mixing with water, and to fibers which form from the compounds. The hydrogels and fibers are antibacterial and not toxic towards mammalian cells. Such comp...
|
|
WO/2021/255552A1 |
Provided are amino acid based polymerizable compounds and their applications in ophthalmic devices. The amino acid based polymerizable compounds are of formula I: wherein R, R1, and R2 are as described herein.
|
|
WO/2021/250480A1 |
The present disclosure relates to a system for a composition for protein denaturation. The composition includes a non-nucleophilic denaturant comprising a substituted guanidine, wherein the denaturant has a pKa value greater than about 1...
|
|
WO/2021/245660A1 |
The present subject matter provides a composition for sampling body fluids and secretions, preserving nucleic acids, and disinfecting surfaces, the composition comprising: guanidinium thyocianate, sulfite salt, and at least one detergent...
|
|
WO/2021/246779A1 |
The present invention relates to an amide derivative synthesized using probenecid and arginine as reactants, a pharmaceutical composition comprising same for preventing, ameliorating, or treating heart failure, and a method for synthesiz...
|
|
WO/2021/227436A1 |
The present invention belongs to the technical field of medicine synthesis, relates to an antifungal compound, and in particular relates to an antifungal compound, a synthesis method and the use thereof, wherein the antifungal compound i...
|
|
WO/2021/211913A1 |
Novel direct thrombin inhibitors are provided herein, along with methods for their use as anticoagulants. The direct thrombin inhibitors described herein are useful in treating and/or preventing thromboembolism and bleeding or clotting d...
|
|
WO/2021/209345A1 |
The present invention provides derivatives of glutamine of formula (I) and derivatives of arginine of formula (II), and the use of such compounds as flavor modifiers. The invention further provides the use of such derivatives of glutamin...
|
|
WO/2021/184125A1 |
It is provided an anti-aging composition comprising at least one plant extract and a carrier, the at least one plant extract is at least one of Serenoa repens, Hypericum perforatum, Ilex paraguariensis, Ocimum tenuiflorum, Solidago virga...
|
|
WO/2021/174351A1 |
Particular antimicrobials are identified for efficacy in a composition with DispersinB to enhance biofilm dispersal and inactivation of biofilm embedded bacteria.
|
|
WO/2021/171724A1 |
The present invention relates to a metal double salt liquid dispersion comprising an organic solvent and a metal double salt, and characterized in that the metal double salt has a composition represented by the formula: M(R1COO)m-x-y(OH)...
|
|
WO/2021/130168A1 |
This invention relates to an ophthalmic formulation comprising lifitegrast, an amino compound, a tonicity-adjusting agent and water, wherein the formulation has an osmolality of 150-330 mOsm/kg. The invention also relates to lifitegrast ...
|
|
WO/2021/127743A1 |
The present disclosure relates to substituted hydroxystilbene compounds and derivatives, specifically 2-substituted hydroxystilbene compounds and derivatives, the synthesis of such compounds and their use in therapy.
|
|
WO/2021/121068A1 |
Disclosed are a macromolecule for promoting the intake of an anticancer drug, and a composition containing same and the use thereof in the preparation of an anticancer drug. The macromolecule has multiple guanidine groups and optionally ...
|
|
WO/2021/079973A1 |
Provided is an onium salt represented by general formula (1). (In general formula (1), X is any n-valent organic group selected from the group consisting of an aromatic group having 6-50 carbon atoms, a heteroaromatic group having 4-50 c...
|
|
WO/2021/056105A1 |
Compositions and methods based on the use of mutated HIV-1 gp120 polypeptides having amino acid substitutions at positions 61, 105, 108, 375, 474, 475 and 476 are described. These mutated HIV-1 gp120 polypeptides, which make the HIV env ...
|
|
WO/2021/054351A1 |
Provided are: a novel membrane permeation enhancer which contains an amino acid-based surfactant and exhibits excellent safety; and a method for enhancing membrane permeation using this membrane permeation enhancer. The amino acid-based ...
|
|
WO/2021/049563A1 |
A photobase generator that comprises a compound including a first skeleton, which is represented by general formula (a), and a second skeleton, which includes a nitrogen atom that has been bonded to the combining site of the first skelet...
|
|
WO/2021/040441A1 |
The present invention relates to a method for preparing a biguanide-based compound with a high yield. More specifically, the present invention relates to a method for preparing a biguanide-based compound, the method comprising the steps ...
|
|
WO/2021/012274A1 |
The present invention provides a preparation method for metformin hydrochloride. The preparation method comprises: heating raw materials comprising dicyandiamide and dimethylamine hydrochloride by means of microwave, and making the two r...
|
|
WO/2021/008845A1 |
The invention relates to a new crystal modification of N-(aminoiminomethyl)-2-aminoethanoic acid, to crystal mixtures and to a method for producing the crystal modification and the crystal mixtures according to the invention.
|
|
WO/2021/008844A1 |
The present invention relates to a novel crystal modification of N-(aminoiminomethyl)-2-aminoethanoic acid and to a process for the production of said crystal modification.
|
|
WO/2021/008843A1 |
The present invention relates to novel crystal modification of N-(aminoiminomethyl)-2-aminoethanoic acid and to a process for producing said crystal modification.
|
|
WO/2021/008846A1 |
The invention relates to a method for producing N-(aminoiminomethyl)-2-aminoethanoic acid containing N-(aminoiminomethyl)-2-aminoethanoic acid in a thermodynamically metastable crystal modification.
|
|
WO/2021/002689A1 |
The present invention relates to a method for producing peramivir trihydrate, which is an inhibitor of neuraminidase infection, as an anti-influenza agent. According to the production method of the present invention, peramivir trihydrate...
|
|
WO/2020/262455A1 |
The present invention provides a means for increasing the solubility of even a poorly soluble amino acid without changing to an expensive peptide and also without changing the pH, and is characterized in that at least two kinds of amino ...
|
|
WO/2020/242948A1 |
The application is drawn to 18F-radiolabeled residualizing agents and biomolecules and methods for radiolabeling biomolecules with radioactive fluorine atoms. The biomolecules have an affinity for particular types of cells and may specif...
|
|
WO/2020/206534A1 |
The present technology generally relates to a chlorhexidine system comprising chlorhexidine or a salt thereof and metallic particles (such as silver and/or gold) wherein the chlorhexidine is conjugated to the surface of the metallic part...
|
|
WO/2020/210252A1 |
A process to extract carbon from hydrophobic waste comprises: combining the hydrophobic waste with an oxide of an active metal to form a storable, moisture-resistant feedstock for high-temperature processing; heating the feedstock in a f...
|
|
WO/2020/191348A1 |
Therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A and arginine gingipain B, are disclosed, as well as the use thereof for the treatment of disorders associated with P. gingivalis ...
|
|
WO/2020/184797A1 |
The present invention relates to: an eco-friendly method capable of synthesizing an unnatural amino acid-based antibacterial and antibiotic preservative, which has excellent antibacterial and antibiotic performance, in a high yield and w...
|
|
WO/2020/179671A1 |
This invention provides: a curable resin composition including a specific polymer precursor, a nonionic compound B, and at least one compound selected from the group consisting of a polymerizable compound and a photosensitive compound, w...
|
|
WO/2020/176825A1 |
This disclosure relates to methods of managing cancer using bis-biguanide compounds, such as alexidine, and pharmaceutical compositions comprising the same. In certain embodiments, this disclosure relates to methods of treating lung canc...
|
|
WO/2020/139300A2 |
The present invention relates to a pharmaceutical combination comprising granulocyte-colony stimulating factor (G-CSF) and a biguanide compound for treating a patient with cancer with a targeted therapy in combination with chemotherapies.
|
|
WO/2020/120637A1 |
The application relates to a compound of formula (I) or a pharmaceutical salt thereof of formula (II), as well as to a process to obtain said compound and a process to obtain said salt. Additionally disclosed is the compound of formula (...
|
